Systemic lupus erythematosus in a multiethnic cohort (LUMINAXXXIX): Relationship between hormone replacement therapy and disease activity over time [2]

Lupus

Volumn 15, Issue 9, 2006, Pages 621-622

  Fernandez M ^b   McGwin Jr , G ^c,d   Bertoli, A M ^b   Calvo Alen J ^b   Alarcón, Graciela S ^a,b  

^a 830 Faculty Office Tower ^*  (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; ETHNOLOGY; HORMONE SUBSTITUTION; HUMAN; LETTER; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SOCIOECONOMICS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AFRICAN AMERICANS; CONTROLLED CLINICAL TRIALS; ESTROGEN REPLACEMENT THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LINEAR MODELS; LOGISTIC MODELS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTICENTER STUDIES; POSTMENOPAUSE; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 33750532721     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306071924     Document Type: Letter

References (10)

1. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995; 122: 430-433.
2. Meier CR, Sturkenboom MC, Cohen AS, Jick H. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol 1998; 25: 1515-1519.
3. Cooper GS, Dooley MA, Treadwell EL, St. Clair EW, Gilkeson GS. Hormonal and reproductive risk factors for development of systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1830-1839.
4. Buyon JP, Petri MA, Kim MY et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142: 953-962.
5. Walker AM. Confounding by indication. Epidemiology 1996; 7: 335-336.
6. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-3412.
7. Khanna D, Park GS, Paulus HE et al. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum 2005; 52: 3030-3038.
8. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrics 1983; 70: 41-55.
9. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-763.
10. D'Agostino RB, Jr, Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Med 1998; 17: 2265-2281.